- ¥1070 - 3770
- Solarbio
- 北京
- IP5930
- 2026年08月14日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
PF-04991532
- 库存：
999
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1215197-37-7
- 规格：
10mg/5mg/25mg
| 规格： | 10mg | 产品价格： | ¥1880.00 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ¥1070.00 |
| 规格： | 25mg | 产品价格： | ¥3770.00 |
| CAS | 1215197-37-7 |
| 英文名称 | PF-04991532 |
| 分子式 | C18H19F3N4O3 |
| 分子量 | 396.36 |
| 规格 | 5mg ; 10mg ; 25mg |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷藏运输 |
| SMILES | C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F |
| InChIKey | GKMLFBRLRVQVJO-ZDUSSCGKSA-N |
| InChI | InChI=1S/C18H19F3N4O3/c19-18(20，21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6，8-11，13H，1-4，7H2，(H，27，28)(H，22，24，26)/t13-/m0/s1 |
| PubChem CID | 46181428 |
| 靶点 | Glucokinase |
| 通路 | Metabolic Enzyme&Protease |
| 背景说明 | PF-04991532 是一种有效的肝选择性葡萄糖激酶激活剂。 |
| 生物活性 | PF-04991532 is a potent， hepatoselective glucokinase activator with EC50s of 80 and 100 nM in human and rat， respectively.[1] |
| IC50 | EC50: 80 nM (glucokinase in human)， 100 nM (glucokinase in rat)[1] |
| In Vitro | PF-04991532 is a potent， hepatoselective glucokinase activator with EC50s of 80 nM in human and 100 nM in rat and also a Phase 2 clinical candidate. Mechanistic experiments conducted in freshly isolated primary rat hepatocytes treated for 1 hour with PF-04991532 show increased 2-[14C]-deoxyglucose uptake (EC50?=1.261 μM) and increased glucose oxidation (EC50=5.769 μM). Additionally， PF-04991532 decreases the production of glucose from 1-[14C]-lactate in a dose dependent manner (EC50?=0.626 μM). In isolated rat hepatocytes， PF-04991532 increases the expression of G6Pase compare to cells treated only with 100 nM glucagon， and the greatest increase in G6Pase mRNA expression is in the presence of 25 mM glucose， 100 nM glucagon and PF-04991532[1]. |
| In Vivo | A single dose of PF-04991532 increases the glucose infusion rate in order to maintain hyperglycemia. Despite the elevations in plasma triglycerides， surprisingly， hepatic triglycerides in rats dosed with 19 days of PF-04991532 are identical to vehicle treated GK rats. In an additional cohort treated for 28 days， identical hepatic lipid concentrations are observed between vehicle and rats dosed with PF-04991532 (Vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31). In rats treated with PF-04991532， there is increased expression of lipogenic gene expression such as acetyl-CoA carboxylase (ACC)， ATP citrate lyase (ACLY)， and fatty acid synthase (FAS)[1]. |
| 细胞实验 | Primary rat hepatocytes are used to determine the expression of G6Pase. 50，000 freshly isolated rat hepatocytes are incubated in Williams E media overnight supplemented with 100 nM dexamethasone， 1×ITS， and 1×PenStrep. The following morning the media is aspirated， and changed to DMEM no glucose media supplemented with either 5 mM glucose， 25 mM glucose， 1 μM insulin， 100 nM glucagon， or 10 μM PF-04991532. Following 2 hours the media is aspirated， washed twice， and 100 μL of RLT is added to the cells. RNA is extracted with a RNeasy kit[1]. |
| 动物实验 | 13 week old male Goto Kakizaki rats with in-dwelling carotid artery and jugular vein catheters are used in this study. Surgeries are performed one day before shipping. Upon arrival， animals are individually housed， allowed ad libitum chow， and acclimated to their new environment for 6 to 7 days. Animals are randomly assigned either a 100 mg/kg PF-04991532 treatment or vehicle control treatment and orally gavaged at 5 mL/kg. On the day of the experiment， 0.5% Methyl cellulose vehicle is used in vehicle-treated rats. Studies are performed in unstressed， awake， chronically catheterized rats using the insulin clamp technique， in combination with [3-3H] glucose. At the end of the in vivo studies， rats are euthanized[1]. |
| 数据来源文献 | [1]. Erion DM， et al. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139. |
| 单位 | 瓶 |
| 表格1 | |*|1mg|5mg|10mg|$$|1mM|2.523mL|12.6148mL|25.2296mL|$$|5mM|0.5046mL|2.523mL|5.0459mL|$$|10mM|0.2523mL|1.2615mL|2.523mL| |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
用张力计等测定。以水柱的长度（单位：厘米）表示土壤对水的吸力即基质势时，数字的幅度过大，因此 R． K． Schofield取其对数以 PF表示之。 100厘米的水柱相当于 100克 /平方厘米的压力， PF=2，永久凋萎点约相当于 15个大气压， PF=4.2。
血小板因子Ⅲ（PF3）有效性测定 【参考范围】被检者血浆与正常富含血小板血浆（PRP）及乏血小板血浆（PPP）分别反应，后者较前者凝血时间（检测器法）延长不超过5s.【影响因素】1.最好采用硅化或塑料注射器，玻璃试管等需涂硅处理或使用塑料制品。因为玻璃可以激活凝血反应。 2.较理想的抗凝剂应首选枸橼酸钠。 3.止血带不应扎得太紧，时间最好不超过5min，医学教|育网搜集整理并强调采血顺利，以防激活凝血反应。 4.PF3有效测定的准确性取决于富含
上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 人血小板因子-4 ( PF-4 )ELISA 试剂盒 ( 用于血清、血浆、细胞培养上清液和其它生物体液内 ) 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗人 Platelet Factor 4 单抗包被于酶标板上，标准品和样品中的 PF-4与单抗结合，加入生物
技术资料暂无技术资料 索取技术资料
PF-04991532
¥1070 - 3770
